To validate the contribution to antitumor effect of cytotoxic T cells in this combination therapy, CD8+ T cells were depleted using antibodies against CD8 (aCD8) in 4T1 tumor-bearing mice treated with QD-Cat-RGD-based RT (Supplementary Fig. 12a). The gene discussed is CD8A; the disease is neoplasm.